Low-dose aspirin does not reduce adverse heart, lung outcomes in stable COVID patients: study
Oct 19, 2021
Contrary to some clinical observations, aspirin and apixaban (Eliquis) do not reduce the rate of major adverse cardiovascular or pulmonary outcomes in stable outpatients with symptomatic COVID-19, researchers...
Secondary analysis gives blood thinner apixaban nod over warfarin
Feb 24, 2020
Apixaban (Eliquis) may present fewer risks for stroke patients than warfarin, the study found. Meanwhile, anticoagulant use has risen in nursing homes.
Clinical Briefs for Thursday, January 2
Jan 01, 2020
First generics of blood thinner Eliquis approved… FDA receives $91 million funding increase for 2020 … Few pharmacies provide antibiotic disposal instructions, survey shows
Experimental drug prevents blood clots from forming in legs and lungs
Dec 11, 2012
The experimental drug Eliquis prevented blood clots in the legs and lungs and kept them from recurring, according to a new study. Patients who took the medicine were 81% less likely to have symptoms of...